Bellicum Pharmaceuticals Inc (BLCM.OQ)
Tue, May 8 2018
* BELLICUM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
* BELLICUM PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
* BELLICUM PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
* BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501
* BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017
BRIEF-Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501
* BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF CANCER RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501
* BELLICUM PHARMA SAYS EFFECTIVE FEB 20, BOARD APPROVED INCREASE IN SIZE OF BOARD TO 8 MEMBERS - SEC FILING Source text: (http://bit.ly/2BMB6hN) Further company coverage:
* BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES
Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.
Jan 30 Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.
- A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
- Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap
- The Kite Killer - TapImmune And Marker Merger Challenges Gilead
- Bellicum Pharmaceuticals: Will This CAR-TCR Innovator Deliver Robust Profits?
- 3 Things In Biotech, April 13: Roche Pipes Up, Cara Updates, Bellicum Marches On
- Bellicum FDA Hold Is Lifted, Time To Get Back To Business